Payment overview · 2025
General Payments
$240.18
9 reported records · 8 companies
Healthcare provider profile · identity verified
Mark J Kolar, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BURLINGTON, KY · NPI 1356389829
Verified facts
What the public records show
CMS Open Payments records show Mark J Kolar, M.D. received $240.18 in general payments during 2025 across 9 reported records.
Exact Sciences Corporation accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $113.20 | 47.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.87 | 9.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.36 | 8.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.55 | 7.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.49 | 7.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.43 | 7.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.58 | 6.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.70 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.18 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $113.20 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 94 |
| Lisinopril | Lisinopril | 229 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 65 |
| Omeprazole | Omeprazole | 190 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 188 | 42 |
| Metformin Hcl | Metformin Hcl | 163 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 46 |
| Glipizide | Glipizide | 129 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 34 |
| Furosemide | Furosemide | 104 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 22 |
| Lovastatin | Lovastatin | 91 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 24 |
| Simvastatin | Simvastatin | 82 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 24 |
| Gabapentin | Gabapentin | 76 | 23 |
| Allopurinol | Allopurinol | 72 | 19 |
| Trazodone Hcl | Trazodone Hcl | 69 | 15 |
| Metformin Hcl Er | Metformin Hcl | 66 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 17 |
| Spironolactone | Spironolactone | 59 | 20 |
| Atenolol | Atenolol | 58 | 18 |
| Losartan Potassium | Losartan Potassium | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 57 | 15 |
| Valsartan | Valsartan | 53 | 11 |
| Meloxicam | Meloxicam | 52 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 22 |
| Donepezil Hcl | Donepezil Hcl | 50 | 14 |
| Alendronate Sodium | Alendronate Sodium | 49 | 15 |
| Ozempic | Semaglutide | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Carvedilol | Carvedilol | 44 | 12 |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | 11 |
| Eliquis | Apixaban | 39 | 14 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | 12 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 18 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Prednisone | Prednisone | 32 | 29 |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 12 |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Celecoxib | Celecoxib | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.18 · 9 records | Exact Sciences Corporation | Cologuard Collection Kit, ELIQUIS, INSPIRE, JARDIANCE, Kerendia, Leqembi, NURTEC ODT, Ozempic, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error